ARTICLE | Clinical News
XaraColl regulatory update
January 3, 2017 9:18 PM UTC
FDA issued a refusal to file letter for an NDA from Innocoll for XaraColl bupivacaine collagen-matrix implants to treat postsurgical pain. According to the company, FDA said the NDA was “not sufficien...
BCIQ Company Profiles